WEBH:XETRA:XETRA-Amundi MSCI USA UCITS ETF Acc EUR (EUR)

ETF | Others |

Last Closing

USD 37.645

Change

0.00 (0.00)%

Market Cap

USD 0.86B

Volume

6.38K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
USUP:XETRA UBS(Lux)Fund Solutions – MSC..

N/A

USD 1.07B
CA1:XETRA Circus SE

-0.20 (-0.98%)

USD 0.51B
7V0:XETRA Darwin AG

+1.20 (+4.41%)

USD 0.08B
TY3S:XETRA WisdomTree US Treasuries 10Y 3..

N/A

N/A
ABCH:XETRA 21Shares Bitcoin Cash ETP

+0.59 (+4.74%)

N/A
8PSB:XETRA Invesco Physical Markets PLC O

-0.03 (-0.10%)

N/A
AXTZ:XETRA 21Shares Tezos staking ETP

+0.21 (+4.52%)

N/A
42FB:XETRA AI/ML Innovations Inc.

+0.01 (+21.95%)

N/A
BTIC:XETRA Invesco Physical Bitcoin ETN E..

+1.76 (+1.99%)

N/A
2BTD:XETRA 2BTD

+0.48 (+1.51%)

N/A

ETFs Containing WEBH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.86B 60% D- 43% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike